Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 83

Similar articles for PubMed (Select 22870450)

1.

Treatment strategies for osteoarthritis patients with pain and hypertension.

Verdecchia P, Angeli F, Mazzotta G, Martire P, Garofoli M, Gentile G, Reboldi G.

Ther Adv Musculoskelet Dis. 2010 Aug;2(4):229-40. doi: 10.1177/1759720X10376120.

2.

Effects of the cyclooxygenase inhibiting nitric oxide donator naproxcinod versus naproxen on systemic blood pressure in patients with osteoarthritis.

White WB, Schnitzer TJ, Fleming R, Duquesroix B, Beekman M.

Am J Cardiol. 2009 Sep 15;104(6):840-5. doi: 10.1016/j.amjcard.2009.05.014.

PMID:
19733721
4.

The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.

Sowers JR, White WB, Pitt B, Whelton A, Simon LS, Winer N, Kivitz A, van Ingen H, Brabant T, Fort JG; Celecoxib Rofecoxib Efficacy and Safety in Comorbidities Evaluation Trial (CRESCENT) Investigators.

Arch Intern Med. 2005 Jan 24;165(2):161-8. Erratum in: Arch Intern Med. 2005 Mar 14;165(5):551.

PMID:
15668361
5.

Effects of naproxcinod on blood pressure in patients with osteoarthritis.

White WB, Schnitzer TJ, Bakris GL, Frayssinet H, Duquesroix B, Weber M.

Am J Cardiol. 2011 May 1;107(9):1338-45. doi: 10.1016/j.amjcard.2010.12.046. Epub 2011 Mar 2.

PMID:
21371681
6.
7.

Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors.

Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.

Am J Manag Care. 2002 Oct;8(15 Suppl):S401-13.

8.

Naproxcinod, a new cyclooxygenase-inhibiting nitric oxide donator (CINOD).

Geusens P.

Expert Opin Biol Ther. 2009 May;9(5):649-57. doi: 10.1517/14712590902926071 . Review.

PMID:
19392579
9.
10.

Cyclooxygenase-inhibiting nitric oxide donators for osteoarthritis.

Wallace JL, Viappiani S, Bolla M.

Trends Pharmacol Sci. 2009 Mar;30(3):112-7. doi: 10.1016/j.tips.2009.01.001. Epub 2009 Feb 21.

PMID:
19230986
11.

Naproxcinod: AZD 3582, HCT 3012, naproxen nitroxybutylester, nitronaproxen, NO-naproxen.

[No authors listed]

Drugs R D. 2007;8(4):255-8. Review.

PMID:
17596112
12.

Efficacy and safety of naproxcinod in the treatment of patients with osteoarthritis of the knee: a 13-week prospective, randomized, multicenter study.

Schnitzer TJ, Kivitz A, Frayssinet H, Duquesroix B.

Osteoarthritis Cartilage. 2010 May;18(5):629-39. doi: 10.1016/j.joca.2009.12.013. Epub 2010 Feb 16.

13.

Cyclo-oxygenase-2 inhibitors: when should they be used in the elderly?

Savage R.

Drugs Aging. 2005;22(3):185-200. Review.

PMID:
15813652
14.

Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis.

Whelton A, White WB, Bello AE, Puma JA, Fort JG; SUCCESS-VII Investigators.

Am J Cardiol. 2002 Nov 1;90(9):959-63.

PMID:
12398962
15.

COX-2-specific inhibitors and the kidney: effect on hypertension and oedema.

Whelton A.

J Hypertens Suppl. 2002 Sep;20(6):S31-5. Review.

PMID:
12683425
16.
17.

Efficacy, safety, and tolerability of the cyclooxygenase-inhibiting nitric oxide donator naproxcinod in treating osteoarthritis of the hip or knee.

Karlsson J, Pivodic A, Aguirre D, Schnitzer TJ.

J Rheumatol. 2009 Jun;36(6):1290-7. doi: 10.3899/jrheum.081011. Epub 2009 May 1.

18.

COX-2 selective inhibitors in the treatment of osteoarthritis.

Laine L, White WB, Rostom A, Hochberg M.

Semin Arthritis Rheum. 2008 Dec;38(3):165-87. doi: 10.1016/j.semarthrit.2007.10.004. Epub 2008 Jan 4. Review.

PMID:
18177922
19.

New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.

Hochberg MC.

Semin Arthritis Rheum. 2002 Dec;32(3 Suppl 1):4-14. Review.

PMID:
12528069
20.

Nitronaproxen: AZD 3582, HCT 3012, Naproxen Nitroxybutylester, NO-Naproxen.

[No authors listed]

Drugs R D. 2006;7(4):262-6. Review.

PMID:
16784252
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk